pages · PDF
Nearly every chronic disease traces upstream to three biological failures: systemic inflammation, insulin resistance, and mitochondrial ATP shortage. Leading practitioners describe a four-compound stack — MOTS-c, Epitalon, BPC-157, Thymosin Alpha-1 — addressing all three root causes with no mechanism overlap. The 'irreducible minimum' for lifelong optimization. Mandatory staggered introduction (BPC-157 alone → +MOTS-c → +TA-1 → +Epitalon over 8 weeks) prevents the hs-CRP > 3.0 paradoxical-fatigue trap. Seasonal optimization syncs Epitalon cycles with solstice / equinox transitions.
Unlock: Top 4 Forever — The Irreducible Longevity Stack
Enter your details to get instant access to this free guide.
No spam. We respect your privacy.
“These guides saved me weeks of research. The evidence ratings alone changed how I approach my protocols.”
-- Verified DoseCraft user
Why this matters
If you've been told longevity is a buffet of 30 supplements and a 6-figure clinic membership — the literature describes a different model. Research suggests nearly every chronic disease traces upstream to three biological failures: systemic inflammation, insulin resistance, and mitochondrial ATP shortage. Address those three substrates and downstream pathology loses its substrate. Leading practitioners describe a four-compound stack — MOTS-c, Epitalon, BPC-157, Thymosin Alpha-1 — addressing all three root causes simultaneously, with each compound earning its place through a unique mechanism that none of the others replicate. The literature describes this as the 'irreducible minimum' for lifelong optimization. No bro-science. No name-drops.
What you'll learn
- Why nearly every chronic disease traces upstream to three failures — inflammation, insulin resistance, and ATP shortage — and why addressing the three is more durable than treating downstream pathology
- How MOTS-c (encoded in mitochondrial DNA, the only mtDNA-encoded peptide in clinical use) activates AMPK, restores insulin sensitivity, and forces fatty-acid oxidation at the mitochondrial level
- Why Epitalon's telomerase activation resets circadian rhythm AND silences senescent-cell inflammation — and why 20-day cycles, 2–3×/year, outperform daily dosing
- How BPC-157 functions as the multi-pathway anti-inflammatory floor that lets the other three compounds do their work without fighting baseline inflammation
- Why Thymosin Alpha-1 (FDA-approved adjunctive therapy in 35+ countries) recalibrates T-cells rather than boosting or suppressing them — and why immune intelligence beats immune amplification
- Why the staggered 8-week introduction (BPC-157 alone → +MOTS-c → +TA-1 → +Epitalon) is mandatory — and what happens when users skip it
- The hs-CRP > 3.0 paradoxical-fatigue trap: why MOTS-c on inflamed mitochondria depletes ATP instead of building it, and how BPC-157 priming prevents it
- How to track the protocol on bloodwork (hs-CRP, fasting insulin, HbA1c, homocysteine, TG/HDL) without falling into supplement-stack overconfidence
The protocol at a glance
Dose
MOTS-c 5–10 mg/week TOTAL (split into 2–3 injections) · Epitalon 500 mcg–1 mg/day · BPC-157 500 mcg–1 mg/day · Thymosin Alpha-1 1 mg/day
Frequency
MOTS-c 2–3×/week SubQ fasted, pre-training · Epitalon SubQ at bedtime · BPC-157 SubQ daily · Thymosin Alpha-1 SubQ daily
Cycle
MOTS-c: 12 weeks on / 4 weeks off · Epitalon: 10–20 days on, then 3–6 months off (2–3 cycles per year; run before bed) · BPC-157: no cycling for acute use; 8–12 weeks on / 2–4 weeks off for extended >3-month maintenance · Thymosin Alpha-1: daily long-term, no cycling — FDA-approved for extended use
Timeline
BPC-157 inflammation reduction: 2–4 weeks · MOTS-c metabolic shift (fasting glucose, exercise capacity): 4–8 weeks · TA-1 immune recalibration (frequency of illness, recovery speed): 8–12 weeks · Epitalon circadian + subjective vitality shift: within the first 10-day cycle · Full integrated stack response on the bloodwork panel: 12–16 weeks
Cautions
Staggered introduction is mandatory — not optional. Week 1–2 BPC-157 alone (lower baseline inflammation), Week 3–4 add MOTS-c (only after CRP confirms substrate is ready), Week 5–6 add Thymosin Alpha-1, Week 7–8 add the first Epitalon cycle. If hs-CRP > 3.0 at baseline, do NOT add MOTS-c until BPC-157 has lowered baseline inflammation — MOTS-c on inflamed mitochondria triggers AMPK overstimulation, which produces an oxidative burst that depletes ATP instead of building it (the paradoxical-fatigue trap). Active malignancy: BPC-157's VEGF angiogenesis is contraindicated until oncology sign-off. Active autoimmune flare: pause TA-1 — its T-cell recalibration is for steady-state immune intelligence, not acute disease activity. Pregnancy or breastfeeding: full washout. Under 21 years of age. This is a research synthesis, not medical advice — coordinate with a physician familiar with peptide protocols and run baseline bloodwork before starting.
Is this for you?
- Healthy adults 30+ seeking durable healthspan extension without the over-stacking failure mode (30 supplements, no measurable endpoints, no mechanism coherence)
- Users with elevated hs-CRP, fasting insulin in the 7–15 mIU/L range, or HbA1c 5.4–5.9% — early metabolic-and-inflammation drift that hasn't crossed into clinical disease
- Adults 40+ noticing the classic age-driven shifts (slower recovery, declining exercise capacity, sleep architecture loss, more frequent minor illness) seeking a coherent root-cause intervention
- Users coming off a successful condition-reversal protocol (Hashimoto, PCOS, gut, Wolverine) seeking the maintenance substrate that prevents drift back toward the original pathology
- Users on the 'Trilogy for Life' budget tier (BPC-157 + MOTS-c + Methylene Blue) ready to expand into the full four-compound stack for broader coverage
- Active malignancy or recent malignancy in the past 12 months — BPC-157's VEGF-driven angiogenesis is contraindicated until oncology sign-off
- Active autoimmune flare — pause TA-1 until disease activity is controlled; the protocol is for steady-state immune-intelligence rebuild, not acute flare management
- Pregnancy or breastfeeding
- Organ transplant on anti-rejection medication — coordinate with transplant team; TA-1's immune-recalibration mechanism is theoretically incompatible with iatrogenic immunosuppression
- Under 21 years of age
The mechanism — why it works
The Three Root Causes framework — the upstream model
Standard preventive medicine treats chronic disease as a downstream catalog: cardiovascular disease, type-2 diabetes, autoimmunity, neurodegeneration, sarcopenia, cancer. The literature describes a different model — nearly every entry in that catalog traces upstream to three converging biological failures. Systemic inflammation drives endothelial dysfunction, insulin signaling disruption, neuroinflammation, and immune dysregulation. Insulin resistance starves tissues of glucose substrate while flooding circulation with the inflammatory IGF-1 / mTOR signaling that accelerates senescence. Mitochondrial ATP shortage strips cells of the energy required for repair, immune surveillance, and homeostatic maintenance — the substrate every other function rests on. The Top 4 Forever stack addresses all three. It is small because the mechanisms don't overlap; adding more compounds without unique mechanism is the over-stacking failure mode that produces a $400/month supplement cabinet and no measurable bloodwork change.
MOTS-c — the mitochondrial commander (encoded in mtDNA)
MOTS-c is the only mitochondrial-DNA-encoded peptide in clinical use — a 16-amino-acid sequence transcribed from the mtDNA 12S rRNA region. Its mechanism is direct: it activates AMP-activated protein kinase (AMPK), the cellular energy sensor that flips metabolism from storage to fat-oxidation mode, restores insulin sensitivity at the muscle and liver level, and triggers mitochondrial biogenesis. Research describes MOTS-c reversing age-associated insulin resistance and improving glucose homeostasis in animal models, with human trials documenting reductions in fasting glucose and HbA1c in metabolically dysregulated cohorts. Dosed fasted before training, MOTS-c amplifies the exercise-induced AMPK signal — practitioners report this synergy is the load-bearing mechanism behind the stack's metabolic effects. Covers Root Cause #2 (insulin resistance) as primary, Root Cause #3 (ATP) as primary.
Epitalon — the genetic mechanic (hTERT / telomerase)
Epitalon is a tetrapeptide (Ala-Glu-Asp-Gly) derived from research on pineal-gland extracts. Its mechanism is the most rare-air capacity in the stack: it activates the hTERT gene that codes for telomerase — the enzyme that maintains telomere length. Telomeres shorten with each cell division; when they reach a critical threshold, the cell enters senescence and begins secreting the SASP (senescence-associated secretory phenotype) inflammatory cytokine pattern. Epitalon research describes measurable telomerase activation, telomere-length stabilization, and a reduction in senescent-cell inflammatory secretion. Equally important: Epitalon resets the pineal-gland regulation of circadian rhythm — patients consistently describe restored sleep architecture (more slow-wave, intact REM, normalized cortisol awakening response) inside the first 10-day cycle. Run 500 mcg–1 mg/day SubQ at bedtime for 10–20 days, 2–3 cycles per year. Continuous daily dosing is not how Epitalon is described in the literature; the short-burst cycle pattern is the validated protocol. Covers Root Cause #1 (inflammation, via senescent-cell silencing) as primary.
BPC-157 — the foundation healer and multi-pathway anti-inflammatory floor
BPC-157 is the master regulator of the VEGF repair system and the broadest-acting anti-inflammatory compound in the longevity catalog. Mechanism: it modulates NF-κB to compress the inflammatory phase of any tissue insult, upregulates IL-10 (the systemic anti-inflammatory cytokine), suppresses TNF-α and IL-6 production, and drives organized angiogenesis at the site of damage. In the Top 4 Forever context, BPC-157 isn't just a tissue-repair compound — it's the anti-inflammatory substrate that lets the other three compounds work. MOTS-c on inflamed mitochondria backfires; TA-1's T-cell recalibration is compromised by chronic baseline inflammation; Epitalon's senescent-cell silencing has to fight upstream pro-inflammatory signal. BPC-157 lowers the baseline so the other mechanisms operate on a clean substrate. This is why the staggered introduction starts with BPC-157 alone for 2 weeks. Covers Root Cause #1 (inflammation) as primary; covers Root Cause #2 and #3 as secondary supportive mechanism.
Thymosin Alpha-1 — the immune intelligence layer
Thymosin Alpha-1 (TA-1) is a 28-amino-acid peptide naturally produced by the thymus gland. The thymus involutes progressively from puberty onward — by age 60 it is largely fatty tissue, producing a small fraction of the T-cell training capacity it had at 20. This is the immunological substrate of age-related immune dysfunction: more frequent illness, slower recovery, declining cancer immunosurveillance, blunted vaccine response, autoimmune drift. TA-1 doesn't 'boost' immunity — boosting is the wrong mental model. It recalibrates: it shifts T-cell differentiation toward functional maturation, normalizes the TH1/TH2 balance, and restores natural-killer and dendritic-cell competence. The compound has FDA-equivalent approval in 35+ countries as adjunctive therapy for hepatitis B, melanoma, and immune reconstitution after chemotherapy. In the longevity context: it's the compound that maintains immune intelligence into decades when the thymus alone can no longer produce it. Covers Root Cause #1 (inflammation, via balanced immune response that does not overshoot into chronic activation) as primary.
The coverage matrix — no redundancy, no gaps
The four compounds were not assembled by accident. The selection process described in the literature is rigorous: clinical or strong experimental evidence, unique mechanism (no redundancy with the others in the stack), favorable long-term safety profile, coverage of at least one primary root cause, cost-effective relative to impact. Mapped to the three root causes: BPC-157 covers inflammation as primary (and contributes secondarily to the other two via tissue-repair signaling). MOTS-c covers insulin resistance and ATP shortage as primary. TA-1 covers the immune-dysregulation arm of inflammation as primary. Epitalon covers inflammation (via senescent-cell silencing) and contributes to ATP shortage indirectly through circadian-rhythm restoration. The result: 3 primary coverage points for inflammation (the heaviest firepower, because inflammation is the most upstream of the three), 1 primary for insulin resistance, 2 primary for ATP shortage. Every root cause is covered; nothing is redundant. Compounds that don't make the stack (GHK-Cu, TB-500, Selank, Semax) are excellent in their specific contexts but fail one of the irreducible-minimum criteria — usually 'unique mechanism vs the others' or 'covers a primary root cause.'
Seasonal optimization — solstice / equinox cycling
Leading practitioners describe adjusting the stack seasonally to match the body's natural rhythms. The pattern: Epitalon cycles are timed with the solstice / equinox transitions — January (winter solstice aftermath, deepest circadian disruption from low daylight) and September (fall equinox, preparing telomere maintenance before winter immune challenge). Thymosin Alpha-1 frequency ramps up in winter (October through February — immune challenge peaks with cold/flu season and shortened daylight). MOTS-c intensity ramps up in summer (May through August — higher training volume and heat-stress adaptation demand more metabolic support). BPC-157 remains the constant — it runs continuously regardless of season because the anti-inflammatory floor is a non-seasonal substrate. The seasonal-cycling principle is an optimization, not a requirement — the standard protocol works without it — but practitioners with longer experience consistently describe the seasonal pattern as the difference between 'stack works' and 'stack works optimally.'
Foundational levers (not optional)
The research describes each as an independent driver. The protocol reduces their negative impact but doesn't eliminate it.
Train fasted on MOTS-c days
MOTS-c's AMPK activation amplifies the same signaling pathway exercise triggers. Injecting fasted, 30–60 minutes pre-training, stacks the two signals — the combined AMPK burst is described as the load-bearing mechanism behind the stack's metabolic improvements. Eating before training blunts the AMPK signal (insulin opposes AMPK); training fed on MOTS-c days reduces the efficacy meaningfully.
Sleep is a structural variable
Epitalon's circadian effect operates on a sleep substrate. Under-slept patients on the Top 4 Forever stack consistently respond more slowly across every endpoint. 7–8 hours, consistent timing, dark room, no screens 60 minutes before bed. The peptide protocol amplifies sleep architecture — it cannot substitute for it.
Continuous glucose monitor for the first 8 weeks
A 14-day CGM trial (Levels, NutriSense, or pharmacy-script Dexcom) during the MOTS-c introduction window produces more actionable data than any single bloodwork draw. Watch post-meal glucose excursions narrow as insulin sensitivity restores. Many users discover dietary triggers they'd never identified — and the data closes the feedback loop between protocol and behavior change.
Resistance training is the upstream lever
Muscle is the largest insulin-sensitive tissue in the body and the primary site of MOTS-c's metabolic effect. 3–4 resistance training sessions per week, progressive loading, is the substrate the peptide protocol operates on. Cardio is supplementary; resistance is non-negotiable for the metabolic arm of the protocol to perform.
What you'll feel — week by week
Weeks 1–2 (BPC-157 alone)
BPC-157 begins NF-κB modulation within days. Many users describe reduced joint stiffness, lower baseline 'on-fire' systemic feeling, and improved sleep quality (BPC-157's systemic anti-inflammatory effect). The cognitive layer often clears first — vagal-nerve signaling responds to inflammation reduction before structural markers shift. Track hs-CRP at the 2-week mark — confirm baseline inflammation has moved before introducing MOTS-c.
Weeks 3–4 (+ MOTS-c)
MOTS-c enters the protocol. First few injections may produce mild fatigue for 2–4 hours post-dose (AMPK activation is metabolically expensive); resolves as mitochondrial biogenesis catches up. Fasting glucose begins trending down by day 10 of MOTS-c. Exercise capacity shifts noticeably — many users describe a clear improvement in steady-state cardio output and recovery between sets. Post-meal glucose excursions narrow (CGM data confirms this directly).
Weeks 5–6 (+ Thymosin Alpha-1)
TA-1 added. The immune-recalibration effect builds over 4–8 weeks rather than appearing acutely. Many users describe a subtle but durable shift: fewer minor illnesses, faster resolution when they do occur, more consistent energy through the day. The TA-1 effect is less viscerally dramatic than MOTS-c's metabolic shift but is the most durable arm of the protocol.
Weeks 7–8 (+ Epitalon first cycle)
First 10–20 day Epitalon cycle. The circadian-rhythm shift is often the most subjectively dramatic — users describe deeper, more architectural sleep within 3–5 nights, more coherent dream content, more reliable wake-time without alarm. Cortisol awakening response normalizes. The Epitalon cycle ends after 10–20 days; the circadian benefit persists for months because the pineal-gland reset is durable rather than dose-dependent.
Weeks 12–16 (full integrated stack)
First objective bloodwork recheck. hs-CRP should be trending toward < 1.0 mg/L. Fasting insulin trending toward < 5 mIU/L. HbA1c trending toward < 5.2%. TG/HDL ratio trending toward < 1.5. Homocysteine trending toward < 8 µmol/L. The full integrated stack response is measurable at this timepoint — and this is where many users transition from 'I think this is working' to 'the panel confirms what I'm feeling.' This is also the timepoint to plan the next 12-week cycle: MOTS-c off-cycle (4 weeks), second Epitalon cycle timed for January or September, TA-1 continuous, BPC-157 maintenance.
What could go wrong
Common (no action)
- Mild fatigue for 2–4 hours after the first 2–3 MOTS-c doses — AMPK activation is metabolically expensive; resolves as mitochondrial biogenesis catches up
- Vivid dreams or improved sleep in BPC-157 week 1 — common systemic effect; benign
- Subtle mood shift in Epitalon cycle (calmer, more grounded) — circadian rhythm normalization; benign
- Mild injection-site reaction (transient warmth, small bruise) — rotate sites; benign
Watch + adjust
- Paradoxical fatigue after MOTS-c introduction — strong signal that baseline inflammation was not adequately lowered; stop MOTS-c, return to BPC-157 alone for 2–4 more weeks, recheck hs-CRP before reintroducing
- Fasting insulin or HbA1c not improving after 8 weeks on MOTS-c — add dietary intervention (reduce refined carbs); MOTS-c alone is insufficient if dietary insulin load is high
- New unexplained symptoms during TA-1 introduction (joint pain, rash, fatigue) — pause TA-1; possible immune reaction or unmasking of latent autoimmunity
- hs-CRP rising despite BPC-157 + TA-1 — rule out infection, autoimmune flare, or significant dietary/stress drift before adjusting peptide dose
Stop + seek care
- Active malignancy diagnosis discovered during the protocol — stop BPC-157 immediately until oncology sign-off
- Acute illness or infection — pause MOTS-c and Epitalon; increase TA-1 (immune resource demand); continue BPC-157 (anti-inflammatory floor)
- Surgery or major injury — continue BPC-157 (increase to 1 mg 2×/day at injury site if applicable); add TB-500 if soft-tissue; pause others until recovery substrate stabilizes
- Severe allergic reaction at any injection site — emergency care
Bloodwork — what to track
Primary integrated panel: hs-CRP (systemic inflammation — BPC-157 + TA-1 efficacy; target < 1.0 mg/L; baseline / 8 wk / quarterly), Fasting Insulin (insulin sensitivity — MOTS-c efficacy; target < 5 mIU/L; baseline / 8 wk / quarterly), HbA1c (90-day glucose average — MOTS-c efficacy; target < 5.2%; baseline / 12 wk), Homocysteine (methylation + cardiovascular inflammation; target < 8 µmol/L; baseline / 6 months), TG/HDL ratio (cardiovascular + metabolic substrate; target < 1.5; baseline / quarterly), CBC with Differential (immune cell populations — TA-1 efficacy; baseline / 12 wk), Comprehensive Metabolic Panel (liver / kidney / electrolytes; baseline / 12 wk). Optional add-ons: oxidized LDL (deeper inflammation marker), GlycA (NMR-based composite inflammation), ApoB (CV substrate), DHEA-S (HPA-axis substrate), IGF-1 (mTOR pathway tracking — relevant if running >12 months continuous). Full bloodwork target table + 12-week tracking worksheet in the paid pack.
Frequently asked
Why staggered introduction? Can't I just start all four compounds at once?
No — and this is the most common protocol failure for users who skip the discipline. The staggered 8-week introduction exists because the four compounds have different substrate requirements. MOTS-c needs a low-inflammation baseline to produce metabolic gains (high CRP causes the paradoxical-fatigue trap). TA-1's T-cell recalibration is compromised by acute inflammation. Epitalon's circadian reset is amplified by a clean inflammatory and metabolic substrate. Starting BPC-157 alone for 2 weeks lowers baseline inflammation; adding MOTS-c in week 3 introduces the metabolic load on a primed substrate; adding TA-1 in week 5 introduces immune recalibration with the inflammatory floor already lowered; adding Epitalon in week 7 layers the circadian + telomerase capacity on top of the now-stable foundation. Skipping the stagger is the leading cause of the paradoxical-fatigue trap and inconsistent response.
What is the hs-CRP > 3.0 trap? Why is this the most important safety screen in the protocol?
hs-CRP > 3.0 mg/L indicates systemic inflammation that is also active at the mitochondrial level — inflamed mitochondria have impaired electron-transport function. MOTS-c activates AMPK, which forces mitochondria into high-output mode. On inflamed mitochondria, this produces an oxidative burst — reactive oxygen species output spikes, the electron-transport chain leaks electrons rather than producing ATP, and the net effect is ATP DEPLETION rather than ATP increase. The user experiences this as paradoxical fatigue: more tired on MOTS-c, not less. If hs-CRP > 3.0 at baseline, run BPC-157 alone for 4 weeks (rather than 2), recheck CRP, and only introduce MOTS-c once CRP is < 2.0 ideally < 1.0. This single screen prevents the majority of bad first-impressions of the Top 4 Forever stack.
I can't afford the full stack — what's the 'Trilogy for Life' alternative?
The Trilogy for Life budget tier is BPC-157 + MOTS-c + Methylene Blue. It covers two of the three root causes (inflammation via BPC-157 + MB; insulin resistance + ATP via MOTS-c + MB) at roughly half the monthly cost — primarily because Methylene Blue is pharmacy-grade pennies-on-the-dollar relative to TA-1's $150–300/month. The Trilogy lacks the immune-intelligence layer (TA-1) and the telomerase + circadian capacity (Epitalon). For a user under 40 with no immune concerns and good sleep architecture, Trilogy is a viable starting point. For a user 50+ or with frequent illness, the immune-intelligence layer is the load-bearing piece — TA-1 is hard to substitute. The practitioner consensus: start with Trilogy if budget is the constraint, add TA-1 first when budget allows, add Epitalon last (because the 20-day cycle × 2–3/year amortizes to a low monthly cost — $15–35/month — so it's the easiest add).
Why is Epitalon dosed in 10–20 day bursts instead of daily continuous?
Epitalon's mechanism is durable rather than dose-dependent. The 10–20 day cycle is sufficient to produce measurable telomerase activation and pineal-gland circadian reset — extending dosing beyond that window does not proportionally increase the effect, and runs the theoretical risk of telomerase activation in cells that should not be activated (oncological caution principle). The literature describes 2–3 cycles per year as the validated protocol. Practitioners report the circadian-rhythm benefit persists for 3–6 months after each cycle ends. Timing the cycles with January (post-winter-solstice) and September (fall equinox / pre-winter immune ramp) leverages the natural circadian-pressure windows.
Can Thymosin Alpha-1 really run daily forever with no cycling?
Yes — and this is the empirical pattern in countries where TA-1 is regulatorily approved as adjunctive therapy. The mechanism is recalibration, not stimulation: TA-1 doesn't push T-cells harder, it normalizes their differentiation and function. There is no receptor desensitization or feedback-suppression mechanism that requires cycling. The FDA-equivalent approvals in 35+ countries explicitly cover long-term adjunctive use in hepatitis B (often years of daily dosing) and immune reconstitution post-chemotherapy. Practitioners report no decrement in effect over multi-year continuous dosing. Cycling TA-1 is unnecessary; users who cycle it (out of habit from other peptides) report symptom return during off-weeks, confirming the daily continuous protocol.
What does 'forever' actually mean here? Are these compounds really safe long-term?
The 'forever' framing applies most cleanly to BPC-157 and Thymosin Alpha-1 — both have multi-year safety data and no known mechanism for cumulative harm. MOTS-c cycles 12 weeks on / 4 weeks off rather than running continuously (the AMPK pathway benefits from periodic rest). Epitalon runs in 10–20 day bursts 2–3 times per year — the cumulative annual exposure is small. The literature describes the four-compound stack as the irreducible MINIMUM — not the irreducible maximum. Users may add condition-specific compounds (KPV for autoimmune drift, GHK-Cu for skin / collagen, Semax for cognitive demand windows) and rotate them in / out as conditions warrant. The Top 4 stays constant; the rotational slot adapts. Annual bloodwork (the panel in the bloodwork summary section) is the safety substrate — peptide protocols without bloodwork tracking are operating blind.
Cited research
Verified Vendors
Where to get these compounds
MOTS-c, Epitalon, BPC-157, and Thymosin Alpha-1 are research-grade peptides — the longevity catalog is MyOasis Labs' deepest formulary (the four compounds plus rotational slot options: KPV, GHK-Cu, Semax, Methylene Blue pharmaceutical grade). Source all from the verified vendor below; confirm third-party batch testing on every vial. Reconstitution worksheets and 12-week tracking spreadsheet included in the bloodwork pack.
Peptide Partners
Practitioner-tier research peptides
HPLC + Mass-Spec verified · Free replacement on failed third-party tests
MyOasis Labs
Widest catalog — injectables, oral caps, blends
Third-party lab tested · Every batch
Hydro Research Peptides
Research-grade peptides — 20% off your order
Research peptides · newest addition to the verified roster
Affiliate disclosure: DoseCraft earns a small commission on orders made through these vendor links — at no extra cost to you. We only partner with vendors that pass our internal vendor-rubric audit.
Ready for the full experience?
DoseCraft gives you AI-powered protocol building, 90+ compound library, dose tracking, and evidence-rated stacks from leading practitioners.
Get Started — Try DoseCraft NowNot medical advice — educational only. These guides are for informational and research purposes only. Always consult a licensed healthcare professional before starting any peptide protocol.